<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28208744</article-id><article-id pub-id-type="pmc">5334612</article-id><article-id pub-id-type="doi">10.3390/md15020032</article-id><article-id pub-id-type="publisher-id">marinedrugs-15-00032</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Uncovering Adiponectin Replenishing Property of Sujiaonori Algal Biomaterial in Humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ngatu</surname><given-names>Nlandu Roger</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-15-00032">1</xref><xref rid="c1-marinedrugs-15-00032" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Ikeda</surname><given-names>Mitsunori</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-15-00032">1</xref></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-15-00032">2</xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Mamoru</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-15-00032">2</xref></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Masataka</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-15-00032">1</xref></contrib><contrib contrib-type="author"><name><surname>Kanbara</surname><given-names>Sakiko</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-15-00032">1</xref></contrib><contrib contrib-type="author"><name><surname>Nojima</surname><given-names>Sayumi</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-15-00032">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Long</surname><given-names>Paul</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-marinedrugs-15-00032"><label>1</label>Graduate School of Health &#x00026; Nursing Sciences, University of Kochi, Kochi 781-8515, Japan; <email>mikeda@cc.u-kochi.ac.jp</email> (M.I.); <email>inoue@cc.u-kochi.ac.jp</email> (M.I.); <email>kanbara@cc.u-kochi.ac.jp</email> (S.K.); <email>nojimas@cc.u-kochi.ac.jp</email> (S.N.)</aff><aff id="af2-marinedrugs-15-00032"><label>2</label>Faculty of Nutrition, University of Kochi, Kochi 781-8515, Japan; <email>watana@cc.u-kochi.ac.jp</email> (H.W.); <email>m-tanaka@cc.u-kochi.ac.jp</email> (M.T.)</aff><author-notes><corresp id="c1-marinedrugs-15-00032"><label>*</label>Correspondence: <email>doc.rogerngatu@gmail.com</email>; Tel./Fax: +81-888-478-633</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2017</year></pub-date><volume>15</volume><issue>2</issue><elocation-id>32</elocation-id><history><date date-type="received"><day>21</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The replenishment of adiponectin&#x02014;an adipocyte-derived hormone with salutary health effects&#x02014;has recently been proposed as a new approach to treat hypertension, also ameliorate cardiovascular and metabolic risks. We conducted a prospective placebo-controlled, non-randomized and investigator-blinded dietary intervention study to evaluate the health effects of dietary intake of Sujiaonori (<italic>Ulva/Enteromorpha prolifera M&#x000fc;ller</italic>) algal biomaterial (SBM), especially on adiponectin production, blood pressure (BP), and body mass index (BMI) in human subjects. Participants (<italic>N</italic> = 32) were divided into two equally sized groups (<italic>n</italic> = 16 for each group): SBM group (subjects supplemented with 3 g SBM powder twice a day during meal) and the control group (subjects who took 3 g of a supplement made of 70% corn starch powder and 30% spinach twice a day) for four weeks. Two health survey questionnaires (dietary and current health questionnaires) were completed anonymously, saliva sampling was done for adiponectin measurement by ELISA, and blood pressure (BP) and anthropometric parameters were measured at baseline and four weeks later. Student paired <italic>t</italic>-test was performed to compare baseline and post-intervention data on outcome variables between the two study groups. Results showed a 2.24-fold increase in adiponectin level in SBM group (2.81 and 6.26 ng/mL at baseline and at the end of study, respectively) (<italic>p</italic> &#x0003c; 0.01); whereas no significant change was observed in controls (3.58 and 3.51 ng/mL, respectively) (<italic>p</italic> &#x0003e; 0.05). In SBM subjects, an improvement of BP profile was noted with a significant decrease in systolic BP (<italic>p</italic> &#x0003c; 0.01). A positive correlation was found between SBM supplementation and adiponectin level, whereas an inverse correlation was noted between SBM supplementation and blood pressure, and also BMI. These findings suggest that SBM-increased adiponectin level and improved BP in a sample of Japanese young adults, and has the potential to improve blood pressure in humans.</p></abstract><kwd-group><kwd>adiponectin</kwd><kwd>BMI</kwd><kwd>blood pressure</kwd><kwd>dietary supplementation</kwd><kwd>Sujiaonori</kwd></kwd-group></article-meta></front><body><sec id="sec1-marinedrugs-15-00032"><title>1. Introduction</title><p>Adiponectin&#x02014;an adipocyte-derived secretory factor that promotes insulin sensitivity and cell survival&#x02014;is reported to decrease inflammation, regulate energy homeostasis, and exert salutary activities on cardiovascular health [<xref rid="B1-marinedrugs-15-00032" ref-type="bibr">1</xref>,<xref rid="B2-marinedrugs-15-00032" ref-type="bibr">2</xref>]. A previous study by Okamoto and colleagues found that adiponectin has an antiatherogenic effect [<xref rid="B3-marinedrugs-15-00032" ref-type="bibr">3</xref>], and other studies have associated adiponectin deficiency with diabetes, hypertension, atherosclerosis, coronary heart disease (CHD), and cerebral vascular diseases [<xref rid="B4-marinedrugs-15-00032" ref-type="bibr">4</xref>,<xref rid="B5-marinedrugs-15-00032" ref-type="bibr">5</xref>,<xref rid="B6-marinedrugs-15-00032" ref-type="bibr">6</xref>]. In addition, a number of clinical studies have suggested that adiponectin has a protective effect against cancer [<xref rid="B7-marinedrugs-15-00032" ref-type="bibr">7</xref>,<xref rid="B8-marinedrugs-15-00032" ref-type="bibr">8</xref>]. This cluster of diseases could be alleviated through pharmacological interventions that restore the decreased adiponectin levels. Thus, researchers have been attempting to find compounds that would produce similar biological effects as adiponectin or increase the endogenous adiponectin [<xref rid="B9-marinedrugs-15-00032" ref-type="bibr">9</xref>,<xref rid="B10-marinedrugs-15-00032" ref-type="bibr">10</xref>,<xref rid="B11-marinedrugs-15-00032" ref-type="bibr">11</xref>,<xref rid="B12-marinedrugs-15-00032" ref-type="bibr">12</xref>]. Recent animal experiments on AdipoRon&#x02014;a newly discovered adiponectin receptor (AdipoR) agonist with similar effects as adiponectin&#x02014;have suggested that it could be a promising therapeutic agent for the treatment of obesity-related diseases such as type-2 diabetes and cardiovascular disorders [<xref rid="B13-marinedrugs-15-00032" ref-type="bibr">13</xref>,<xref rid="B14-marinedrugs-15-00032" ref-type="bibr">14</xref>].</p><p>Sujiaonori&#x02014;the Japanese name for <italic>Enteromorpha prolifera M&#x000fc;ller</italic> [<xref rid="B15-marinedrugs-15-00032" ref-type="bibr">15</xref>,<xref rid="B16-marinedrugs-15-00032" ref-type="bibr">16</xref>], which belongs to the family of <italic>Ulvacea</italic> in the order of <italic>Ulvales</italic>&#x02014;is an edible green river alga that grows in Shimanto River, in Kochi, Japan. This algal species is rich in fiber (60%&#x02013;65% dry weight), contains bioactive compounds (polyphenols, polyunsaturated fatty acids, vitamins), and is reported to have antioxidant, anti-inflammatory, immunostimulatory, and hypolipidemic properties [<xref rid="B17-marinedrugs-15-00032" ref-type="bibr">17</xref>,<xref rid="B18-marinedrugs-15-00032" ref-type="bibr">18</xref>,<xref rid="B19-marinedrugs-15-00032" ref-type="bibr">19</xref>,<xref rid="B20-marinedrugs-15-00032" ref-type="bibr">20</xref>]. We conducted a dietary intervention study and an experimental study on the effects of Sujiaonori-based supplement on adiponectin level, cardiovascular health, the gastrointestinal system, and a number of chronic inflammatory disorders. In this study, saliva&#x02014;which has recently been used as an alternative non-invasive bio-specimen in clinical studies related to cardiovascular and metabolic disorders [<xref rid="B21-marinedrugs-15-00032" ref-type="bibr">21</xref>]&#x02014;was used for adiponectin measurement. The present report highlights findings related to the effects of dietary intake of Sujiaonori algal biomaterial (SBM) on adiponectin, blood pressure (BP), and body mass index (BMI) in apparently healthy human subjects.</p></sec><sec id="sec2-marinedrugs-15-00032"><title>2. Results and Discussion</title><sec id="sec2dot1-marinedrugs-15-00032" sec-type="subjects"><title>2.1. Characteristics of Participants</title><p>Of the 38 subjects enrolled, 32 completed the study, including 27 (84.4%) nursing students (age range: 20&#x02013;29 years) and five (15.6%) teaching staff (age range: 31&#x02013;54 years). The brief self-administered diet history questionnaire (BDHQ) survey questionnaire used in our study revealed the daily intake of different nutrients by the study participants. The estimated daily calorie intake for the SBM group was 1303.9 &#x000b1; 478.9 kcal and 1480.8 &#x000b1; 630.1 kcal before and after dietary intervention, respectively, and it was 1284.1 &#x000b1; 461.5 kcal and 1315.6 &#x000b1; 391.8 kcal in controls (<italic>p</italic> &#x0003e; 0.05). Except for alcohol intake (which was reduced in each group during the study period), no significant difference was observed with regard to the daily intake of nutrients within each group, and also when comparing SBM subjects to controls (<italic>p</italic> &#x0003e; 0.05). The analysis of baseline blood pressure (BP) indicated that six subjects (three SBM, three controls subjects; 18.7%) had a personal history of hypertension, 10 (six SBM subjects, four controls; 32%) had either prehypertension (systolic BP: 120&#x02013;139 mmHg) or high blood pressure (systolic BP: 140 mmHg or higher). On the other hand, nine subjects (28%) had a baseline diastolic BP between 80 and 89 mmHg or higher, including four SBM subjects and five controls. Assessment of the BMI profile of participants revealed that two (6.2%) SBM subjects were overweight (BMI &#x02265; 25 kg/m<sup>2</sup>); all other subjects (93.8%) had a BMI &#x0003c; 25 kg/m<sup>2</sup>.</p></sec><sec id="sec2dot2-marinedrugs-15-00032"><title>2.2. SBM Supplementation Induces Adiponectin Replenishment</title><p>As shown in <xref ref-type="fig" rid="marinedrugs-15-00032-f001">Figure 1</xref>, a 2.24-fold increase of salivary adiponectin level was observed in the SBM group, from 2.81 at baseline to 6.26 ng/mL and four weeks later (<italic>p</italic> &#x0003c; 0.01), whereas no significant difference was noted in the control group (3.58 ng/mL and 3.51 ng/mL, respectively) (<italic>p</italic> &#x0003e; 0.05). In addition, when both study groups were compared, a markedly higher adiponectin level was observed in the SBM group (<italic>p</italic> &#x0003c; 0.01; vs. control).</p><p>The effects of Sujiaonori on human health have been rarely studied. Animal experiments on sulfated polysaccharides (ulvans) or ulvan fractions from several <italic>Ulva</italic> species have indicated promising health benefits [<xref rid="B22-marinedrugs-15-00032" ref-type="bibr">22</xref>,<xref rid="B23-marinedrugs-15-00032" ref-type="bibr">23</xref>]. However, the effects of Sujiaonori on cardiovascular health have not been investigated. Our preliminary study showed that SBM supplementation increased adiponectin level close to the highest end of normal value in humans (6.42 ng/mL) [<xref rid="B24-marinedrugs-15-00032" ref-type="bibr">24</xref>]. The administration of exogenous adiponectin as a drug is proposed as an alternative therapeutic approach in the management of cardiovascular and metabolic disorders associated with adiponectin deficiency. Furthermore, other studies have suggested that the discovery of novel pharmacological agents that increase adiponectin level or the development of adiponectin agonists could be an important step in the treatment of these conditions [<xref rid="B25-marinedrugs-15-00032" ref-type="bibr">25</xref>,<xref rid="B26-marinedrugs-15-00032" ref-type="bibr">26</xref>].</p><p>Obviously, natural compounds able to increase the endogenous adiponectin may assist in the prevention of disease initiation in at-risk subjects or may alleviate cardiometabolic disorders [<xref rid="B27-marinedrugs-15-00032" ref-type="bibr">27</xref>]. For example, previous studies have shown that daily intake of <italic>eicosapentaenoic acid</italic> (EPA)&#x02014;one of the omega-3 polyunsaturated fatty acids (PUFA) that are abundant in marine fish meat and oil&#x02014;induced an increase in adiponectin level in mice [<xref rid="B28-marinedrugs-15-00032" ref-type="bibr">28</xref>]. In addition, there are a few natural compounds and plant materials that have been reported to influence adiponectin level. For example, a combination of <italic>docosahexaenoic acid</italic> (DHA, another PUFA) and canola oil [<xref rid="B10-marinedrugs-15-00032" ref-type="bibr">10</xref>], as well as compounds from the medicinal herb <italic>Radix astragali</italic> (such as <italic>astragaloside</italic> II and <italic>isoastragaloside</italic> I [<xref rid="B29-marinedrugs-15-00032" ref-type="bibr">29</xref>]) have increased adiponectin level in animal experiments. Another study by Williams et al. [<xref rid="B30-marinedrugs-15-00032" ref-type="bibr">30</xref>] showed that coffee consumption upregulated adiponectin production; however, this finding was controversial, as other researchers have found that daily intake of coffee did not influence adiponectin level in healthy or sick Japanese men and women [<xref rid="B31-marinedrugs-15-00032" ref-type="bibr">31</xref>]. In our study, a 2.24&#x02013;2.96-fold increase of adiponectin level was observed, and no adverse effects were reported by the SBM subjects. Future comparative clinical investigations could possibly provide knowledge on the optimum doses of Sujiaonori-based supplement that could be beneficial in humans. Furthermore, current smoking is reported to decrease adiponectin, and this reduction can be reversed by quitting smoking [<xref rid="B32-marinedrugs-15-00032" ref-type="bibr">32</xref>,<xref rid="B33-marinedrugs-15-00032" ref-type="bibr">33</xref>]. In our study, no participant smoked, and the intake of fish products and dietary fiber did not vary within the study period. Overall, no significant differences were noted in terms of nutrients intake between the study groups, which suggested that the observed changes in adiponectin level and blood pressure profile were attributable to the supplements used in this preliminary study.</p></sec><sec id="sec2dot3-marinedrugs-15-00032"><title>2.3. Effects of SBM Supplementation on BMI, Blood Pressure, and Correlation between Salivary Adiponectin and Outcome Parameters</title><p><xref ref-type="fig" rid="marinedrugs-15-00032-f002">Figure 2</xref> shows the trend in BMI in each of the study groups before (baseline) and after a 4-week intervention. Though a relatively lower BMI observed in the SBM group and higher BMI in controls at the end-of-study evaluation, no statistically significant change was observed within each group and between the study groups compared to baseline BMI values (<italic>p</italic> &#x0003e; 0.05).</p><p>Regarding blood pressure, after a 4-week supplementation period, a reduction in systolic BP was observed within each of the study groups. Regarding the systolic BP, a statistically significant decrease was observed in the SBM group (<italic>p</italic> &#x0003c; 0.05), whereas a marginally significant reduction was noted in the control group (<italic>p</italic> = 0.0611). When comparing both study groups, no significant change was observed (<italic>p</italic> &#x0003e; 0.05) (<xref ref-type="fig" rid="marinedrugs-15-00032-f003">Figure 3</xref>). In addition, results from this preliminary study also showed a reduction of systolic BP in SBM subjects with a baseline systolic BP of 120 mmHg or higher, including subjects with prehypertension (<italic>p</italic> &#x0003c; 0.01, not shown). Regarding diastolic BP, a decrease was observed in each of the study groups, but not significantly (<italic>p</italic> &#x0003e; 0.05, not shown).</p><p>Hypertension is considered to be the greatest contributor to carotid arteriosclerosis in the Japanese population [<xref rid="B34-marinedrugs-15-00032" ref-type="bibr">34</xref>]. Numerous meta-analyses of large-scale clinical trials have shown that prehypertension increased cardiovascular risk [<xref rid="B35-marinedrugs-15-00032" ref-type="bibr">35</xref>]. Our study showed a reduction of systolic BP in the SBM group, and a positive correlation between SBM supplementation and adiponectin level. In the SBM-supplemented group, adiponectin level was inversely correlated with BMI, and positively with age. No association was found between adiponectin level and other clinical parameters such as diastolic BP and physical activity (not shown).</p><p>To summarize, our study showed that the intake of SBM supplement increased adiponectin level and improved BP in subjects with either prehypertension or high BP at baseline. The latter effect might be attributable mainly to the increased adiponectin level. Considering the beneficial health effects of adiponectin in humans [<xref rid="B1-marinedrugs-15-00032" ref-type="bibr">1</xref>,<xref rid="B5-marinedrugs-15-00032" ref-type="bibr">5</xref>], and given that the upregulation of adiponectin production is reported to ameliorate cardiovascular risk such as prehypertension and hypertension [<xref rid="B36-marinedrugs-15-00032" ref-type="bibr">36</xref>], a food product or supplement that can replenish adiponectin might be beneficial in reversing the disease course of patients with those conditions or eliminating the disease risk in individuals at risk. Thus, SBM has the potential to ameliorate blood pressure and related cardiovascular risks. However, despite the health effects observed, our study has some limitations; it was conducted in young subjects who were apparently healthy, and findings might differ in older subjects. Investigating the effects of SBM supplementation in subjects from different age-groups as well as in individuals with documented cardiovascular and/or metabolic disorders may provide more information on the magnitude of the health benefits of Sujiaonori.</p></sec></sec><sec id="sec3-marinedrugs-15-00032"><title>3. Materials and Methods</title><sec id="sec3dot1-marinedrugs-15-00032" sec-type="subjects"><title>3.1. Study Design, Participants, and Survey Questionnaires</title><p>We conducted a non-randomized, placebo-controlled, investigator-blinded dietary intervention on the health effects of SBM dietary intake from January through August 2016 in Kochi prefecture, Japan. The participants were adult nursing students and teaching staff from the University of Kochi who satisfied the following inclusion criteria: 20 years of age or older, absence of a major health condition, taking no medication, voluntary enrollment, and provision of a signed informed consent form. Individuals with a personal and/or family history of allergy to algal product, ongoing medication, having heart, liver, major brain or kidney disease were not eligible. Of the 38 volunteers who were enrolled; 34 got registered to confirm their participation and received survey sheets, of whom 32 completed the study, including 31 women and 1 man. Two participants who did not undergo the second clinical examination and saliva sampling were excluded for the analysis related to this report (<xref ref-type="fig" rid="marinedrugs-15-00032-f004">Figure 4</xref>).</p><p>Participants were registered and assigned to study groups using their identification numbers; the SBM group comprised odd-numbered subjects who had to take 3 g SBM powder twice daily during mealtimes, control group was even numbered-subjects who received a 3 g mixture of 70% corn starch and 30% Japanese spinach powder twice daily. Dried Sujiaonori and corn starch samples were provided by a local food processing factory. The experimental period was four weeks. SBM powder and control product were prepared at our food science laboratory in the University of Kochi.</p><p>At baseline and four weeks later, the &#x0201c;brief self-administered diet history questionnaire&#x0201d; (BDHQ) and the Current Health Status Questionnaire (CHSQ) were anonymously completed by participants, and anthropometric parameters and blood pressure were measured. In addition, saliva samples were collected at baseline and on day 28 of the study for the measurement of salivary adiponectin. BDHQ&#x02014;which was used to assess the dietary history of participants&#x02014;is a four-page fixed-portion questionnaire that asks about the intake of 58 selected food and beverage items in the previous month (BDHQ questionnaire, University of Tokyo) [<xref rid="B37-marinedrugs-15-00032" ref-type="bibr">37</xref>]. CHSQ was prepared by our research team, and comprised questions related to sociodemographics (gender, age, and occupation), lifestyle-related information (smoking habit, alcohol consumption, and physical exercise), intake of Sujiaonori or other algal food product, history of hypertension or hypotension, and other health conditions.</p></sec><sec id="sec3dot2-marinedrugs-15-00032"><title>3.2. ELISA Assay and Outcome Variables</title><p>For saliva sampling, whole saliva (approximately 5 mL) was collected in tube with a funnel at our laboratory between 8:00 and 9:00 am, at least 60 min prior to brushing teeth, eating, or drinking. Test tubes were placed on ice just after saliva collection and stored at &#x02212;20 &#x000b0;C. Salivary adiponectin was assayed by Enzyme-linked Immunosorbent Assay (ELISA) using a Human Adiponectin ELISA Kit (AssayPro, St Charles, MO, USA) in accordance with the manufacturer&#x02019;s instructions. Briefly, collected samples were centrifuged at 800&#x000d7; <italic>g</italic> for 10 min. Reagents, standards, and saliva samples were prepared at room temperature. First, the excess microplate strips were removed from the plate, and 50 &#x003bc;L of adiponectin standard or saliva sample was added to each of the wells. Then, the wells were covered with a sealing tape and the plate was incubated for 1 h.</p><p>After each well was washed with washing buffer (200 &#x003bc;L), 50 &#x003bc;L of conjugate was added, and the plate was incubated for 30 min. After incubation, the microplate was washed as previously described. Fifty microliters of chromogen substrate were added to each well, and a 10 min incubation was performed. Next, 50 &#x003bc;L stop solution was added to each well, and the color changed from blue to yellow. The absorbance of the microplate was measured at a wavelength of 450 nm. The mean values of the triplicate readings for each standard and sample were calculated. A standard curve was generated, and the graph was plotted with the standard concentrations on the <italic>x</italic>-axis and the corresponding mean 450 nm absorbance on the <italic>y</italic>-axis. The essay was performed in duplicate. The primary outcome variable was the salivary adiponectin level, and the secondary outcome variables were blood pressure (BP), BMI, and health outcomes retrieved from the answers to survey questionnaires. In this paper, only data on salivary biomarker and a selected number of cardiovascular risk parameters (blood pressure, history of hypertension, hypotension, and BMI) are reported. Prehypertension (systolic BP: 120&#x02013;139 mmHg; diastolic BP: 80&#x02013;89 mmHg) and hypertension (systolic BP &#x0003e;139 mmHg; diastolic BP &#x0003e;89 mmHg) were defined according to the American Heart Association [<xref rid="B38-marinedrugs-15-00032" ref-type="bibr">38</xref>].</p></sec><sec id="sec3dot3-marinedrugs-15-00032"><title>3.3. Ethics Approval and Consent to Participate</title><p>Ethical approval of the study protocol was obtained from the ethics committee of the faculty of Nutrition, University of Kochi (Approval reference: No15-10, November 2015). The study protocol was registered in an international trial registry (ISRCTN35616776). Additionally, each participant provided a signed informed consent. This research was conducted in accordance with the rules of the Declaration of Helsinki of 1975, as revised in 2008.</p></sec><sec id="sec3dot4-marinedrugs-15-00032"><title>3.4. Data Analysis</title><p>Stata software version 13 (Stata Corp, College Station, TX, USA) was used for statistical analyses. Continuous outcome variables are described as means or percentages, and comparison between study groups was performed with the use of analysis of variance (one-way ANOVA). For binary variables, data are described as proportions. A Spearman correlation test was performed to assess the association between salivary adiponectin, age, occupation, blood pressure, and BMI; on the other hand, multivariate logistic regression test was used to assess the association between salivary adiponectin and categorical variables (physical exercise, history of intake of algal food product, history of hypertension or hypotension). Statistical significance for <italic>p</italic>-values was set at 0.05.</p></sec></sec><sec id="sec4-marinedrugs-15-00032"><title>4. Conclusions</title><p>Findings from this study suggested that the daily dietary intake of SBM supplement replenished adiponectin and ameliorated BP in subjects with prehypertension. Thus, Sujiaonori represents a source of promising bioactive materials that have a potential to improve blood pressure.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Umebara Makoto from Umebara Design Office, Yukiko Nakaie, Michiyo Muneishi and Yuki Kujime from the University of Kochi, and also Okajima Maiko Kaneko of JAIST, Ishikawa prefecture, Japan, for their support to this study.</p></ack><notes><title>Author Contributions</title><p>N.R.N., S.N. and M.I. wrote the research protocol and participated in data analysis and interpretation as well as drafting the paper; H.W., M.T., M.I., M.I. and S.K. performed bioassays, contributed in data analysis and proofread the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>None declared. Findings from this research were subject to patent application and authors agreed to transfer all related rights to the University of Kochi. This research was funded by the Kochi Prefecture Local Development Fund 2015. The funding institution had no role neither in the design of this research, nor in the collection, analyses, data interpretation, the writing of the manuscript and in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">BDHQ</td><td align="left" valign="top" rowspan="1" colspan="1">brief self-administered diet history questionnaire</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI</td><td align="left" valign="top" rowspan="1" colspan="1">body mass index</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BP</td><td align="left" valign="top" rowspan="1" colspan="1">blood pressure</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CHD</td><td align="left" valign="top" rowspan="1" colspan="1">coronary heart disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DBP</td><td align="left" valign="top" rowspan="1" colspan="1">diastolic blood pressure</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ELISA</td><td align="left" valign="top" rowspan="1" colspan="1">enzyme-linked immunosorbent assay</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SBM</td><td align="left" valign="top" rowspan="1" colspan="1">Sujiaonori biomaterial</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SBP</td><td align="left" valign="top" rowspan="1" colspan="1">systolic blood pressure</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-marinedrugs-15-00032"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>G.I.</given-names></name><name><surname>Febbraio</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Adiponectin sphings into action</article-title>
<source>Nat. Med.</source>
<year>2011</year>
<volume>17</volume>
<fpage>37</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1038/nm0111-37</pub-id>
<pub-id pub-id-type="pmid">21217676</pub-id></element-citation></ref><ref id="B2-marinedrugs-15-00032"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maeda</surname><given-names>N.</given-names></name><name><surname>Shimomura</surname><given-names>I.</given-names></name><name><surname>Kishida</surname><given-names>K.</given-names></name><name><surname>Nishizawa</surname><given-names>H.</given-names></name><name><surname>Matsuda</surname><given-names>M.</given-names></name><name><surname>Nagaretani</surname><given-names>H.</given-names></name><name><surname>Furuyama</surname><given-names>N.</given-names></name><name><surname>Kondo</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Arita</surname><given-names>Y.</given-names></name><etal/></person-group>
<article-title>Diet-induced insulin resistance in mice lacking adiponectin/ACRP30</article-title>
<source>Nat. Med.</source>
<year>2002</year>
<volume>8</volume>
<fpage>731</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1038/nm724</pub-id>
<pub-id pub-id-type="pmid">12068289</pub-id></element-citation></ref><ref id="B3-marinedrugs-15-00032"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>Y.</given-names></name><name><surname>Kihara</surname><given-names>S.</given-names></name><name><surname>Ouchi</surname><given-names>N.</given-names></name><name><surname>Nishida</surname><given-names>M.</given-names></name><name><surname>Arita</surname><given-names>Y.</given-names></name><name><surname>Kumada</surname><given-names>M.</given-names></name><name><surname>Ohashi</surname><given-names>K.</given-names></name><name><surname>Sakai</surname><given-names>N.</given-names></name><name><surname>Shimomura</surname><given-names>I.</given-names></name><name><surname>Kobayashi</surname><given-names>H.</given-names></name><etal/></person-group>
<article-title>Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice</article-title>
<source>Circulation</source>
<year>2002</year>
<volume>106</volume>
<fpage>2767</fpage>
<lpage>2770</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.0000042707.50032.19</pub-id>
<pub-id pub-id-type="pmid">12451000</pub-id></element-citation></ref><ref id="B4-marinedrugs-15-00032"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Satar</surname><given-names>N.</given-names></name><name><surname>Wannamethee</surname><given-names>G.</given-names></name><name><surname>Sarwar</surname><given-names>N.</given-names></name><name><surname>Tchernova</surname><given-names>J.</given-names></name><name><surname>Cherry</surname><given-names>L.</given-names></name><name><surname>Wallace</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Adiponectin and coronary heart disease, a prospective study and meta-analysis</article-title>
<source>Circulation</source>
<year>2006</year>
<volume>114</volume>
<fpage>623</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.618918</pub-id>
<pub-id pub-id-type="pmid">16894037</pub-id></element-citation></ref><ref id="B5-marinedrugs-15-00032"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>S.H.</given-names></name><name><surname>Quon</surname><given-names>M.J.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Koh</surname><given-names>K.K.</given-names></name></person-group>
<article-title>Adiponectin and cardiovascular disease: Response to therapeutic interventions</article-title>
<source>J. Am. Coll. Cardiol.</source>
<year>2007</year>
<volume>49</volume>
<fpage>531</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2006.08.061</pub-id>
<pub-id pub-id-type="pmid">17276175</pub-id></element-citation></ref><ref id="B6-marinedrugs-15-00032"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hui</surname><given-names>X.</given-names></name><name><surname>Lam</surname><given-names>K.S.L.</given-names></name><name><surname>Vanhutte</surname><given-names>P.M.</given-names></name><name><surname>Xu</surname><given-names>A.</given-names></name></person-group>
<article-title>Adiponectin and cardiovascular health: An update</article-title>
<source>Br. J. Pharmacol.</source>
<year>2012</year>
<volume>165</volume>
<fpage>574</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01395.x</pub-id>
<pub-id pub-id-type="pmid">21457225</pub-id></element-citation></ref><ref id="B7-marinedrugs-15-00032"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katira</surname><given-names>A.</given-names></name><name><surname>Tan</surname><given-names>P.H.</given-names></name></person-group>
<article-title>Adiponectin and its receptors signaling: An anti-cancer therapeutic target and its implications for anti-tumor immunity</article-title>
<source>Expert. Opin. Ther. Targets</source>
<year>2015</year>
<volume>19</volume>
<fpage>1105</fpage>
<lpage>1125</lpage>
<pub-id pub-id-type="doi">10.1517/14728222.2015.1035710</pub-id>
<pub-id pub-id-type="pmid">25952656</pub-id></element-citation></ref><ref id="B8-marinedrugs-15-00032"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelesidis</surname><given-names>I.</given-names></name><name><surname>Kelesidis</surname><given-names>T.</given-names></name><name><surname>Mantzoros</surname><given-names>C.S.</given-names></name></person-group>
<article-title>Adiponectin and cancer: A systematic review</article-title>
<source>Br. J. Cancer</source>
<year>2006</year>
<volume>94</volume>
<fpage>1221</fpage>
<lpage>1225</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6603051</pub-id>
<pub-id pub-id-type="pmid">16570048</pub-id></element-citation></ref><ref id="B9-marinedrugs-15-00032"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Hoo</surname><given-names>R.L.</given-names></name><name><surname>Sweeney</surname><given-names>G.</given-names></name><name><surname>Vanhoutte</surname><given-names>P.M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Chu</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>G.</given-names></name><name><surname>Lam</surname><given-names>K.S.</given-names></name></person-group>
<article-title>Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerancein obese mice</article-title>
<source>Endocrinology</source>
<year>2009</year>
<volume>150</volume>
<fpage>625</fpage>
<lpage>633</lpage>
<pub-id pub-id-type="doi">10.1210/en.2008-0999</pub-id>
<pub-id pub-id-type="pmid">18927219</pub-id></element-citation></ref><ref id="B10-marinedrugs-15-00032"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Otvos</surname><given-names>L.</given-names><suffix>Jr.</suffix></name><name><surname>Haspinger</surname><given-names>E.</given-names></name><name><surname>La Russa</surname><given-names>F.</given-names></name><name><surname>Maspero</surname><given-names>F.</given-names></name><name><surname>Graziano</surname><given-names>P.</given-names></name><name><surname>Kovalszky</surname><given-names>I.</given-names></name><name><surname>Lovas</surname><given-names>S.</given-names></name><name><surname>Nama</surname><given-names>K.</given-names></name><name><surname>Hoffmann</surname><given-names>R.</given-names></name><name><surname>Knappe</surname><given-names>D.</given-names></name><etal/></person-group>
<article-title>Design and development of peptide-based adiponectin receptor agonist for cancer treatment</article-title>
<source>BMC. Biotechnol.</source>
<year>2011</year>
<volume>11</volume>
<elocation-id>90</elocation-id>
<pub-id pub-id-type="doi">10.1186/1472-6750-11-90</pub-id>
<pub-id pub-id-type="pmid">21974986</pub-id></element-citation></ref><ref id="B11-marinedrugs-15-00032"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Otvos</surname><given-names>L.</given-names><suffix>Jr.</suffix></name><name><surname>Knappe</surname><given-names>D.</given-names></name><name><surname>Hoffmann</surname><given-names>I.</given-names></name><name><surname>Kovalszky</surname><given-names>I.</given-names></name><name><surname>Olah</surname><given-names>J.</given-names></name><name><surname>Hewitson</surname><given-names>T.D.</given-names></name><name><surname>Stawikowska</surname><given-names>R.</given-names></name><name><surname>Stawiskowski</surname><given-names>M.</given-names></name><name><surname>Cudic</surname><given-names>P.</given-names></name><name><surname>Lin</surname><given-names>F.</given-names></name><etal/></person-group>
<article-title>Development of second generation peptides modulating cellular adiponectin receptor responses</article-title>
<source>Front. Chem.</source>
<year>2014</year>
<volume>2</volume>
<fpage>93</fpage>
<pub-id pub-id-type="doi">10.3389/fchem.2014.00093</pub-id>
<pub-id pub-id-type="pmid">25368867</pub-id></element-citation></ref><ref id="B12-marinedrugs-15-00032"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holland</surname><given-names>W.L.</given-names></name><name><surname>Brozinick</surname><given-names>J.T.</given-names></name><name><surname>Wang</surname><given-names>L.P.</given-names></name><name><surname>Hawkins</surname><given-names>E.D.</given-names></name><name><surname>Sargent</surname><given-names>K.M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Narra</surname><given-names>K.</given-names></name><name><surname>Hoehn</surname><given-names>K.L.</given-names></name><name><surname>Knotts</surname><given-names>T.A.</given-names></name><name><surname>Siesky</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Inhibition of ceramide synthesis ameliorated glucocorticoid, saturated fat, and obesity-induced insulin resistance</article-title>
<source>Cell Metab.</source>
<year>2007</year>
<volume>5</volume>
<fpage>167</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2007.01.002</pub-id>
<pub-id pub-id-type="pmid">17339025</pub-id></element-citation></ref><ref id="B13-marinedrugs-15-00032"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okada-Iwabu</surname><given-names>M.</given-names></name><name><surname>Yamauchi</surname><given-names>T.</given-names></name><name><surname>Iwabu</surname><given-names>M.</given-names></name><name><surname>Honma</surname><given-names>T.</given-names></name><name><surname>Hamagami</surname><given-names>K.</given-names></name><name><surname>Matsuda</surname><given-names>K.</given-names></name><name><surname>Yamaguchi</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>H.</given-names></name><name><surname>Kimura-Someya</surname><given-names>T.</given-names></name><name><surname>Shirouzu</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity</article-title>
<source>Nature</source>
<year>2013</year>
<volume>503</volume>
<fpage>493</fpage>
<lpage>499</lpage>
<pub-id pub-id-type="doi">10.1038/nature12656</pub-id>
<pub-id pub-id-type="pmid">24172895</pub-id></element-citation></ref><ref id="B14-marinedrugs-15-00032"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Lau</surname><given-names>W.B.</given-names></name><name><surname>Yuan</surname><given-names>Y.X.</given-names></name><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>E.H.</given-names></name><name><surname>Koch</surname><given-names>W.J.</given-names></name><name><surname>Ma</surname><given-names>X.L.</given-names></name><etal/></person-group>
<article-title>AdipoRon, the first active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings</article-title>
<source>Am. J. Physiol. Endocrinol. Metab.</source>
<year>2015</year>
<volume>309</volume>
<fpage>E275</fpage>
<lpage>E282</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00577.2014</pub-id>
<pub-id pub-id-type="pmid">26037251</pub-id></element-citation></ref><ref id="B15-marinedrugs-15-00032"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ngatu</surname><given-names>N.R.</given-names></name><name><surname>Ikeda</surname><given-names>M.</given-names></name><name><surname>Kanbara</surname><given-names>S.</given-names></name><name><surname>Inoue</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Umebara</surname><given-names>M.</given-names></name><name><surname>Nojima</surname><given-names>S.</given-names></name></person-group>
<article-title>Potential health effects of green river algae (Aonori) of the LPP complex, with a reference to <italic>Ulva prolifera</italic></article-title>
<source>Int. J. Gen. Med.</source>
<year>2015</year>
<volume>4</volume>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation></ref><ref id="B16-marinedrugs-15-00032"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>A.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Huan</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name></person-group>
<article-title>The sporulation of the green alga <italic>Ulva prolifera</italic> is controlled by changes in photosynthetic electron transport chain</article-title>
<source>Sci. Rep.</source>
<year>2016</year>
<volume>6</volume>
<fpage>24923</fpage>
<pub-id pub-id-type="doi">10.1038/srep24923</pub-id>
<pub-id pub-id-type="pmid">27102955</pub-id></element-citation></ref><ref id="B17-marinedrugs-15-00032"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>S.</given-names></name></person-group>
<article-title>Therapeutic importance of sulfated polysaccharides from seaweeds: Updating the recent findings</article-title>
<source>3 Biotech</source>
<year>2012</year>
<volume>2</volume>
<fpage>171</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1007/s13205-012-0061-9</pub-id>
</element-citation></ref><ref id="B18-marinedrugs-15-00032"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wen</surname><given-names>S.</given-names></name><name><surname>Oin</surname><given-names>S.</given-names></name></person-group>
<article-title>Hypolipidemic and antioxidant properties of a polysaccharide fraction from Enteromorpha prolifera</article-title>
<source>Int. J. Biol. Macromol.</source>
<year>2013</year>
<volume>58</volume>
<fpage>186</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2013.03.048</pub-id>
<pub-id pub-id-type="pmid">23541551</pub-id></element-citation></ref><ref id="B19-marinedrugs-15-00032"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Pei</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Di</surname><given-names>D.</given-names></name></person-group>
<article-title>Polysaccharides from <italic>Enteromorpha prolifera</italic> enhance the immunity of normal mice</article-title>
<source>Int. J. Biol. Macromol.</source>
<year>2014</year>
<volume>64</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2013.11.013</pub-id>
<pub-id pub-id-type="pmid">24296406</pub-id></element-citation></ref><ref id="B20-marinedrugs-15-00032"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name></person-group>
<article-title>Biological activities of green macroalgae <italic>Enteromorpha prolifera</italic> for potential applications</article-title>
<source>MOJ Food Process. Technol.</source>
<year>2016</year>
<volume>2</volume>
<fpage>00048</fpage>
<pub-id pub-id-type="doi">10.15406/mojfpt.2016.02.00048</pub-id>
</element-citation></ref><ref id="B21-marinedrugs-15-00032"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toda</surname><given-names>M.</given-names></name><name><surname>Tsukinoki</surname><given-names>R.</given-names></name><name><surname>Morimoto</surname><given-names>K.</given-names></name></person-group>
<article-title>Measurement of salivary adiponectin levels</article-title>
<source>Acta Diabetol.</source>
<year>2007</year>
<volume>44</volume>
<fpage>20</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1007/s00592-007-0236-8</pub-id>
<pub-id pub-id-type="pmid">17357881</pub-id></element-citation></ref><ref id="B22-marinedrugs-15-00032"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huimin</surname><given-names>Q.</given-names></name><name><surname>Sheng</surname><given-names>J.</given-names></name></person-group>
<article-title>The antihyperlipidemic mechanism of high sulfate content ulvan in rats</article-title>
<source>Mar. Drugs</source>
<year>2015</year>
<volume>13</volume>
<fpage>3407</fpage>
<lpage>3421</lpage>
<pub-id pub-id-type="pmid">26035020</pub-id></element-citation></ref><ref id="B23-marinedrugs-15-00032"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name></person-group>
<article-title>Antioxidant activity of high sulfate content derivative of ulvan in hyperlipidemic rats</article-title>
<source>Int. J. Biol. Macromol.</source>
<year>2015</year>
<volume>76</volume>
<fpage>326</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2015.03.006</pub-id>
<pub-id pub-id-type="pmid">25773592</pub-id></element-citation></ref><ref id="B24-marinedrugs-15-00032"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>Y.</given-names></name><name><surname>Pieczonka</surname><given-names>T.D.</given-names></name><name><surname>Bragiel</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Membrane transporters in salivary exosomes and microvesicles as biomarkers of systemic or oral disease</article-title>
<source>J. Oral Biosci.</source>
<year>2014</year>
<volume>56</volume>
<fpage>110</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.job.2014.06.001</pub-id>
</element-citation></ref><ref id="B25-marinedrugs-15-00032"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Hung</surname><given-names>Y.J.</given-names></name></person-group>
<article-title>Possible new therapeutic approach for obesity-related diseases: role of adiponectin receptor agonists</article-title>
<source>J. Diabetes Investig.</source>
<year>2015</year>
<volume>6</volume>
<fpage>264</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1111/jdi.12263</pub-id>
<pub-id pub-id-type="pmid">25969709</pub-id></element-citation></ref><ref id="B26-marinedrugs-15-00032"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fisman</surname><given-names>E.Z.</given-names></name><name><surname>Tenenbuam</surname><given-names>A.</given-names></name></person-group>
<article-title>Adiponectin: A manifold therapeutic target for meta-bolic syndrome, diabetes, and coronary disease?</article-title>
<source>Cardiovasc. Diabetol.</source>
<year>2014</year>
<volume>13</volume>
<fpage>103</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2840-13-103</pub-id>
<pub-id pub-id-type="pmid">24957699</pub-id></element-citation></ref><ref id="B27-marinedrugs-15-00032"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>S.</given-names></name><name><surname>Quon</surname><given-names>M.J.</given-names></name><name><surname>Koh</surname><given-names>K.K.</given-names></name></person-group>
<article-title>Modulation of adiponectin as a potential therapeutic strategy</article-title>
<source>Atherosclerosis</source>
<year>2014</year>
<volume>233</volume>
<fpage>721</fpage>
<lpage>728</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.01.051</pub-id>
<pub-id pub-id-type="pmid">24603219</pub-id></element-citation></ref><ref id="B28-marinedrugs-15-00032"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lefils-Lacourtablaise</surname><given-names>J.</given-names></name><name><surname>Socorro</surname><given-names>M.</given-names></name><name><surname>G&#x000e9;lo&#x000eb;n</surname><given-names>A.</given-names></name><name><surname>Daira</surname><given-names>P.</given-names></name><name><surname>Debard</surname><given-names>C.</given-names></name><name><surname>Loizon</surname><given-names>E.</given-names></name><name><surname>Guichardant</surname><given-names>M.</given-names></name><name><surname>Dominguez</surname><given-names>Z.</given-names></name><name><surname>Vidal</surname><given-names>H.</given-names></name><name><surname>Lagarde</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>The eicosa-pentaenoic acid metabolite 15-Deoxy-&#x003b4;<sup>12,14</sup>-Prostaglandin J<sub>3</sub> increases adiponectin secretion by adipocytes partly <italic>via</italic> a PPAR&#x003b3;-dependent mechanism</article-title>
<source>PLoS ONE</source>
<year>2013</year>
<volume>8</volume>
<elocation-id>e63997</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0063997</pub-id>
<pub-id pub-id-type="pmid">23734181</pub-id></element-citation></ref><ref id="B29-marinedrugs-15-00032"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>P.J.</given-names></name><name><surname>Senanayake</surname><given-names>V.K.</given-names></name><name><surname>Pu</surname><given-names>S.</given-names></name><name><surname>Jenkins</surname><given-names>D.J.</given-names></name><name><surname>Cornnelly</surname><given-names>P.W.</given-names></name><name><surname>Lamarche</surname><given-names>B.</given-names></name><name><surname>Couture</surname><given-names>P.</given-names></name><name><surname>Charest</surname><given-names>A.</given-names></name><name><surname>Baril-Gravel</surname><given-names>L.</given-names></name><name><surname>West</surname><given-names>S.G.</given-names></name><etal/></person-group>
<article-title>DHA-enriched high-oleic acid oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial</article-title>
<source>Am. J. Clin. Nutr.</source>
<year>2014</year>
<volume>100</volume>
<fpage>88</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.113.081133</pub-id>
<pub-id pub-id-type="pmid">24829493</pub-id></element-citation></ref><ref id="B30-marinedrugs-15-00032"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>C.J.</given-names></name><name><surname>Fargnoli</surname><given-names>J.L.</given-names></name><name><surname>Hwang</surname><given-names>J.J.</given-names></name><name><surname>van Dam</surname><given-names>R.M.</given-names></name><name><surname>Blackburn</surname><given-names>G.L.</given-names></name><name><surname>Hu</surname><given-names>F.B.</given-names></name><name><surname>Mantzoros</surname><given-names>C.S.</given-names></name></person-group>
<article-title>Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: A prospective cohort study</article-title>
<source>Diabetes Care</source>
<year>2008</year>
<volume>31</volume>
<fpage>504</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="doi">10.2337/dc07-1952</pub-id>
<pub-id pub-id-type="pmid">18070989</pub-id></element-citation></ref><ref id="B31-marinedrugs-15-00032"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotani</surname><given-names>K.</given-names></name><name><surname>Fujiwara</surname><given-names>S.</given-names></name><name><surname>Hamada</surname><given-names>T.</given-names></name><name><surname>Tsuzaki</surname><given-names>K.</given-names></name><name><surname>Sakane</surname><given-names>N.</given-names></name></person-group>
<article-title>Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type-2 diabetes</article-title>
<source>Diabetes Care</source>
<year>2008</year>
<volume>31</volume>
<fpage>e46</fpage>
<pub-id pub-id-type="doi">10.2337/dc08-0186</pub-id>
<pub-id pub-id-type="pmid">18445726</pub-id></element-citation></ref><ref id="B32-marinedrugs-15-00032"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsai</surname><given-names>J.S.</given-names></name><name><surname>Guo</surname><given-names>F.R.</given-names></name><name><surname>Chen</surname><given-names>S.C.</given-names></name><name><surname>Lue</surname><given-names>B.H.</given-names></name><name><surname>Chiu</surname><given-names>T.Y.</given-names></name><name><surname>Chen</surname><given-names>C.Y.</given-names></name><name><surname>Hung</surname><given-names>S.H.</given-names></name><name><surname>Chuang</surname><given-names>L.M.</given-names></name><name><surname>Chen</surname><given-names>C.Y.</given-names></name></person-group>
<article-title>Smokers show reduced circulating adiponectin levels and adiponectin mRNA expression in peripheral blood mononuclear cells</article-title>
<source>Atherosclerosis</source>
<year>2011</year>
<volume>218</volume>
<fpage>168</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.04.025</pub-id>
<pub-id pub-id-type="pmid">21605866</pub-id></element-citation></ref><ref id="B33-marinedrugs-15-00032"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotani</surname><given-names>K.</given-names></name><name><surname>Hazama</surname><given-names>A.</given-names></name><name><surname>Hagimoto</surname><given-names>A.</given-names></name><name><surname>Saika</surname><given-names>K.</given-names></name><name><surname>Shigeta</surname><given-names>M.</given-names></name><name><surname>Katanoda</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name></person-group>
<article-title>Adiponectin and smoking status: A systematic review</article-title>
<source>J. Atheroscler. Thromb.</source>
<year>2012</year>
<volume>19</volume>
<fpage>787</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="doi">10.5551/jat.11833</pub-id>
<pub-id pub-id-type="pmid">22653164</pub-id></element-citation></ref><ref id="B34-marinedrugs-15-00032"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishizaka</surname><given-names>N.</given-names></name><name><surname>Ishizaka</surname><given-names>Y.</given-names></name><name><surname>Toda</surname><given-names>E.I.</given-names></name><name><surname>Hashimoto</surname><given-names>H.</given-names></name><name><surname>Nagai</surname><given-names>R.</given-names></name><name><surname>Yamakado</surname><given-names>M.</given-names></name></person-group>
<article-title>Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals</article-title>
<source>Hypertens. Res.</source>
<year>2005</year>
<volume>28</volume>
<fpage>27</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1291/hypres.28.27</pub-id>
<pub-id pub-id-type="pmid">15969252</pub-id></element-citation></ref><ref id="B35-marinedrugs-15-00032"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teramoto</surname><given-names>T.</given-names></name><name><surname>Fujita</surname><given-names>T.</given-names></name><name><surname>Kawamori</surname><given-names>R.</given-names></name><name><surname>Miyazaki</surname><given-names>S.</given-names></name><name><surname>Teramukai</surname><given-names>S.</given-names></name><name><surname>Igarashi</surname><given-names>M.</given-names></name></person-group>
<article-title>OMEGA study: Design, baseline data, metabolic syndrome prevalence in a large-scale observational study of hypertensive patients: The Olmesartan Mega Study to determine the relationship between cardiovacular endpoints and blood pressure goal achievement study</article-title>
<source>Hypertens. Res.</source>
<year>2008</year>
<volume>31</volume>
<fpage>2011</fpage>
<lpage>2017</lpage>
<pub-id pub-id-type="pmid">19098372</pub-id></element-citation></ref><ref id="B36-marinedrugs-15-00032"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>K.</given-names></name><name><surname>Kihara</surname><given-names>S.</given-names></name><name><surname>Ouchi</surname><given-names>N.</given-names></name><name><surname>Kumada</surname><given-names>M.</given-names></name><name><surname>Fujita</surname><given-names>K.</given-names></name><name><surname>Hiuge</surname><given-names>A.</given-names></name><name><surname>Hibuse</surname><given-names>T.</given-names></name><name><surname>Ryo</surname><given-names>M.</given-names></name><name><surname>Nishizawa</surname><given-names>H.</given-names></name><name><surname>Maeda</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>Adiponectin replenishment ameliorates obesity-related hypertension</article-title>
<source>Hypertension</source>
<year>2006</year>
<volume>47</volume>
<fpage>1108</fpage>
<lpage>1116</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.0000222368.43759.a1</pub-id>
<pub-id pub-id-type="pmid">16651465</pub-id></element-citation></ref><ref id="B37-marinedrugs-15-00032"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakata</surname><given-names>S.</given-names></name><name><surname>Tsuchihashi</surname><given-names>T.</given-names></name><name><surname>Oniki</surname><given-names>H.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Arakawa</surname><given-names>K.</given-names></name><name><surname>Sakaki</surname><given-names>M.</given-names></name><name><surname>Kitazono</surname><given-names>T.</given-names></name></person-group>
<article-title>Relationship between salt intake as estimated by a brief self-administered diet-history questionnaire (BDHQ) and 24-h urinary salt excretion in hypertensive patients</article-title>
<source>Hypertens. Res.</source>
<year>2015</year>
<volume>38</volume>
<fpage>560</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1038/hr.2015.35</pub-id>
<pub-id pub-id-type="pmid">25787036</pub-id></element-citation></ref><ref id="B38-marinedrugs-15-00032"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>L.</given-names></name></person-group>
<article-title>New AHA recommendations for blood pressure measurement</article-title>
<source>Am. Fam. Physician</source>
<year>2005</year>
<volume>72</volume>
<fpage>1391</fpage>
<lpage>1398</lpage>
</element-citation></ref></ref-list></back><floats-group><fig id="marinedrugs-15-00032-f001" position="float"><label>Figure 1</label><caption><p>Distribution of salivary adiponectin according to study group. Legend: #, <italic>p</italic>-value less than 0.01 versus baseline value as well as controls; ADN, adiponectin; SD, standard deviation. <xref ref-type="fig" rid="marinedrugs-15-00032-f001">Figure 1</xref> shows an increase of adiponectin level within Sujiaonori algal biomaterial (SBM) group (vs. baseline values) and also when compared to the Control group (<italic>p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="marinedrugs-15-00032-g001"/></fig><fig id="marinedrugs-15-00032-f002" position="float"><label>Figure 2</label><caption><p>Trend of body mass index (BMI) according to study group (<italic>N</italic> = 32). Legend: BMI, body mass index; BMI1, value of body mass index before intervention; BMI2, value of body mass index after intervention; <italic>N</italic>, sample size; SD, standard deviation; SBM, Sujiaonori algal biomaterial. The figure shows a slight reduction of BMI in the SBM group, but the difference was not significant when comparing BMI values before and after SBM supplementation, or control and SBM groups (<italic>p</italic> &#x0003e; 0.05).</p></caption><graphic xlink:href="marinedrugs-15-00032-g002"/></fig><fig id="marinedrugs-15-00032-f003" position="float"><label>Figure 3</label><caption><p>Distribution of blood pressure according to supplementation group. Legend: *, <italic>p</italic>-value less than 0.05 versus baseline value in SBM group; SD, standard deviation; SBM, Sujiaonori algal biomaterial; BP, blood pressure. The figure shows the reduction of systolic BP in both study groups, with a significant difference in the SBM group (<italic>p</italic> &#x0003c; 0.05), whereas a marginally significant difference was noted in controls (<italic>p</italic> = 0.0611). In controls, a reduction of systolic BP was observed, but not significantly (<italic>p</italic> &#x0003e; 0.05). No difference was observed when comparing SBM and control groups (<italic>p</italic> &#x0003e; 0.05).</p></caption><graphic xlink:href="marinedrugs-15-00032-g003"/></fig><fig id="marinedrugs-15-00032-f004" position="float"><label>Figure 4</label><caption><p>Clinical trial protocol on the effects of daily dietary intake of Sujiaonori supplement adiponectin secretion and cardiovascular health. Legend: TEWL, transepidermal water loss.</p></caption><graphic xlink:href="marinedrugs-15-00032-g004"/></fig></floats-group></article>